What is renal medullary carcinoma?
Renal medullary carcinoma (RMC) is a rare and aggressive kidney cancer that mainly affects teenagers and young adults who have sickle cell trait or, less often, another sickle haemoglobin condition such as haemoglobin SC disease.
It starts in the medulla, the inner part of the kidney, near the area where urine collects before draining to the bladder.
RMC was first described in 1995 as the “seventh sickle cell nephropathy”, the seventh kidney problem known to be linked with sickle haemoglobin (Davis et al., 1995). Almost all affected people are of African, Mediterranean, Middle Eastern or South Asian ancestry, the groups in which sickle cell trait is most common.
Every RMC has lost the function of a tumour suppressor gene called SMARCB1 (also known as INI1). For this reason, the World Health Organization (WHO) now calls it SMARCB1-deficient renal medullary carcinoma (Calderaro et al., 2012).
RMC tends to grow and spread quickly, and most people already have spread to other organs when they are diagnosed. It does not respond well to many drugs that work in other kidney cancers. Treatment usually involves platinum-based chemotherapy, and surgery when the cancer is localised. Research into new treatments is very active (Msaouel et al., 2019).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Aggressive carcinoma of the kidney medulla |
| How common | Very rare; well under 1% of kidney cancers |
| Typical age | Teens to 30s; median late 20s |
| Sex | About twice as common in males |
| Key link | Sickle cell trait or other sickle haemoglobin disorders |
| Hallmark | Loss of SMARCB1 (INI1) |
| Side | More often the right kidney |
| Main treatments | Platinum-based chemotherapy; nephrectomy for localised disease; clinical trials |
| Outlook | Serious; most people have spread at diagnosis |
2. Causes and risk factors
Sickle cell trait
People with sickle cell trait carry one copy of the sickle haemoglobin gene (HbAS). Most never have health problems. However, the inner part of the kidney, the medulla, has low oxygen levels, high salt concentration and slow blood flow. In these conditions, red blood cells with sickle haemoglobin can change shape and block small vessels.
Researchers think that repeated low oxygen and injury in the medulla may encourage cells to lose SMARCB1, leading to cancer (Msaouel et al., 2020).
| Factor | Notes |
|---|---|
| Sickle cell trait (HbAS) | Present in most people with RMC |
| Haemoglobin SC disease | Also linked |
| Sickle cell disease (HbSS) | Reported rarely |
| Young age | Most are 10-40 years old |
| Male sex | About twice as common |
| Strenuous physical activity | Suggested as a possible contributor, because it lowers oxygen in the kidney; not proven |
Sickle haemoglobin conditions explained
| Condition | Genes | Usual health effects |
|---|---|---|
| Sickle cell trait (HbAS) | One sickle gene, one normal gene | Usually none; sometimes blood in the urine; small risk of RMC |
| Haemoglobin SC disease (HbSC) | One sickle gene, one haemoglobin C gene | A milder form of sickle cell disease |
| Sickle cell anaemia (HbSS) | Two sickle genes | Pain crises, anaemia, organ damage |
Sickle cell trait is common. It is carried by about 1 in 13 Black Americans and by many people in sub-Saharan Africa, the Mediterranean, the Middle East and India. RMC is very rare, so almost everyone with sickle cell trait will never develop it.
The SMARCB1 gene
SMARCB1 is part of a complex that controls how tightly DNA is packed and which genes are switched on. When it is lost, growth-promoting genes such as MYC become overactive. The same gene is lost in malignant rhabdoid tumours of children.
In RMC, SMARCB1 is usually lost through breaks and rearrangements of chromosome 22, rather than inherited mutations. RMC is not inherited, although the sickle cell trait that predisposes to it is.
Without sickle cell trait
Rarely, a tumour with the same features occurs in someone without a sickle haemoglobin disorder. This is called renal cell carcinoma, unclassified with medullary phenotype.
3. How does it look
On scans
| Feature | Typical appearance |
|---|---|
| Location | Centre of the kidney (medulla), often the right kidney |
| Growth pattern | Infiltrative, spreading through the kidney without clear borders |
| Kidney shape | Often keeps its overall bean shape despite the tumour |
| Contrast | Patchy enhancement, less than the normal kidney |
| Urine-collecting system | Dilatation (caliectasis) from blockage |
| Lymph nodes | Enlarged nodes around the kidney and aorta are common |
| Spread | Lungs, liver, bone, adrenal glands |
Under the microscope
| Feature | Description |
|---|---|
| Pattern | Sheets, glands, cords and a “reticular” or sieve-like (cribriform) pattern |
| Background | Dense fibrous (desmoplastic) tissue with inflammation |
| Cells | Large cells with prominent nucleoli; some look rhabdoid |
| Sickled red cells | Often visible in blood vessels |
| SMARCB1 (INI1) stain | Lost in tumour cells, the key test |
| Other stains | Keratin and PAX8 positive; OCT3/4 sometimes positive |
How RMC differs from other kidney cancers
| Feature | Renal medullary carcinoma | Clear cell kidney cancer |
|---|---|---|
| Typical age | Teens to 30s | 60s and 70s |
| Main link | Sickle haemoglobin | Smoking, obesity, high blood pressure, VHL |
| Starts in | Medulla (inner kidney) | Cortex (outer kidney) |
| Gene change | SMARCB1 loss | VHL loss |
| Response to VEGF tablets | Poor | Often good |
| Main drug treatment | Platinum chemotherapy | Immunotherapy and VEGF tablets |
4. Symptoms
Common symptoms
- Blood in the urine (haematuria), the most common symptom
- Pain in the side (flank) or back
- Pain in the tummy
- Weight loss without trying
- Tiredness
- Fever
- A lump in the side or tummy
Symptoms of spread
| Site | Possible symptoms |
|---|---|
| Lungs | Cough, breathlessness, chest pain |
| Lymph nodes | Swelling in the neck or groin; back pain from nodes in the abdomen |
| Bones | Bone pain, fracture |
| Liver | Pain under the right ribs, jaundice |
| Brain | Headache, seizures (rare) |
When to seek medical advice
Anyone with sickle cell trait or sickle cell disease who notices blood in the urine should see a doctor promptly. Blood in the urine is very common in sickle cell trait and is usually harmless, but it should never be ignored. Doctors should arrange imaging of the kidneys, usually a CT or MRI, rather than assuming the cause is benign (Beckermann et al., 2017).
5. Diagnosis
| Test | Purpose |
|---|---|
| Urine test | Confirms blood in the urine |
| Haemoglobin electrophoresis | Confirms sickle cell trait or other haemoglobin disorders |
| CT or MRI of the abdomen | Shows the tumour and lymph nodes |
| CT of the chest | Checks for lung spread |
| Biopsy | Confirms the diagnosis, including loss of SMARCB1 |
| Bone scan, brain MRI or PET-CT | If symptoms suggest spread |
| Blood tests | Blood count, kidney and liver function |
RMC can be confused with urothelial carcinoma (a cancer of the urine-collecting system), collecting duct carcinoma or lymphoma. A SMARCB1 stain is essential in any young person with an aggressive kidney tumour and a sickle haemoglobin disorder (Msaouel et al., 2019).
6. Treatment
Treatment should be planned at a specialist centre with experience in rare kidney cancers, ideally with access to clinical trials.
Localised disease
| Treatment | Notes |
|---|---|
| Radical nephrectomy | Removal of the whole kidney, often with nearby lymph nodes |
| Chemotherapy | Often considered before or after surgery because the risk of spread is high |
| Close follow-up | Frequent scans to detect early recurrence |
Advanced (metastatic) disease
| Treatment | Notes |
|---|---|
| Platinum-based chemotherapy | The standard first treatment, such as carboplatin with paclitaxel, or cisplatin-based combinations; responses occur in about a third of people (Shah et al., 2017) |
| Gemcitabine with doxorubicin | Sometimes used after first-line chemotherapy |
| Clinical trials | Strongly recommended; drugs that target EZH2, proteasomes and other pathways are being studied |
| Surgery | Removal of the kidney may be considered after a good response to chemotherapy |
| Radiotherapy | To relieve pain or treat individual metastases |
Treatments that work poorly
Drugs that work well in common kidney cancers, such as VEGF-targeted tablets (for example sunitinib) and mTOR inhibitors, have little effect in RMC. Responses to immune checkpoint inhibitors have been reported in individual patients, but in a phase 2 trial, nivolumab with ipilimumab did not work and some cancers grew faster (Soeung et al., 2025).
Care for sickle haemoglobin disorders
People with sickle cell disease need careful management of their blood condition during cancer treatment, including hydration, infection prevention and sometimes blood transfusions. Sickle cell trait itself rarely needs treatment.
Side effects
| Treatment | Possible side effects |
|---|---|
| Nephrectomy | Pain, bleeding, infection; reduced kidney reserve |
| Platinum chemotherapy | Nausea, low blood counts, infections, hair loss, nerve damage, hearing changes, kidney strain |
| Paclitaxel | Hair loss, nerve tingling, allergic reactions |
| Radiotherapy | Tiredness, skin changes, local effects |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Chemotherapy | Given through a drip, usually as a day patient, in cycles every 3 weeks |
| Scans | CT every 2-3 cycles to check the response |
| Surgery | Hospital stay of about 3-7 days; return to normal activities over 4-6 weeks |
| Fertility | Sperm or egg storage should be discussed before chemotherapy |
RMC in children and teenagers
RMC is among the kidney cancers seen in older children and adolescents, although it is much rarer than Wilms tumour. Young people are treated by paediatric or teenage and young adult cancer teams, often within international study groups. Treatment follows the same principles: surgery for localised disease and platinum-based chemotherapy, with a strong emphasis on clinical trials.
7. Outlook (prognosis)
| Measure | Approximate figures |
|---|---|
| Spread at diagnosis | About 2 in 3 to 4 in 5 people |
| Median survival, all patients | About 13 months in a multicentre study (Shah et al., 2017) |
| Localised disease removed by surgery | Some people remain free of disease long term |
The outlook is serious, but survival has improved with platinum chemotherapy and better supportive care. A growing understanding of the biology of SMARCB1 loss is leading to new trial drugs (Msaouel et al., 2020).
In the large multicentre study, nearly all people with spread at diagnosis needed chemotherapy, and those whose cancer responded to platinum treatment lived longer. People treated with surgery for localised disease had the best results, although relapse was still common (Shah et al., 2017).
Factors linked with a better outlook
- Localised disease that can be completely removed
- Good response to chemotherapy
- Good general health
8. Follow-up
| Follow-up | Typical schedule |
|---|---|
| CT of the chest, abdomen and pelvis | Every 2-3 months at first, because recurrence can be fast |
| Blood tests | Kidney function, blood count |
| Kidney function checks | Lifelong after nephrectomy, especially with sickle cell trait |
| Sickle cell care | Continued haematology support for people with sickle cell disease |
9. Living with renal medullary carcinoma
- Protect your remaining kidney: stay well hydrated and avoid regular use of anti-inflammatory painkillers such as ibuprofen
- Ask about fertility preservation before chemotherapy
- Tell relatives that sickle cell trait runs in families, so they can be tested
- Seek support from young adult cancer services and kidney cancer charities
- Ask about clinical trials at the start and at each change of treatment
- Get psychological support; a serious diagnosis at a young age is hard for patients and families
10. Frequently asked questions
| Question | Answer |
|---|---|
| Does sickle cell trait mean I will get kidney cancer? | No. RMC is very rare, even among people with sickle cell trait |
| Is RMC inherited? | The cancer itself is not, but sickle cell trait is |
| Should people with sickle cell trait be screened? | Routine screening is not recommended, but blood in the urine should always be investigated |
| Why don’t standard kidney cancer drugs work? | RMC has different biology, driven by loss of SMARCB1 |
| Can children get RMC? | Yes, rarely, usually older children and teenagers |
| Should I join a clinical trial? | Specialists strongly recommend considering trials |
| Can I live with one kidney? | Yes. One healthy kidney is enough for normal life, but it needs protecting |
| Does exercise cause RMC? | This has been suggested but not proven; staying active is still encouraged |
11. Questions to ask your care team
- Has the tumour been tested for SMARCB1 (INI1) loss?
- Has the cancer spread?
- Which chemotherapy do you recommend, and why?
- Is surgery an option for me now or later?
- Are there clinical trials I could join?
- Should my family be tested for sickle cell trait?
Resources
- Beckermann, K.E. et al. (2017) ‘Renal medullary carcinoma: establishing standards in practice’, Journal of Oncology Practice, 13(7), pp. 414-421.
- Calderaro, J. et al. (2012) ‘SMARCB1/INI1 inactivation in renal medullary carcinoma’, Histopathology, 61(3), pp. 428-435.
- Davis, C.J., Mostofi, F.K. and Sesterhenn, I.A. (1995) ‘Renal medullary carcinoma: the seventh sickle cell nephropathy’, American Journal of Surgical Pathology, 19(1), pp. 1-11.
- Msaouel, P. et al. (2019) ‘Updated recommendations on the diagnosis, management, and clinical trial eligibility criteria for patients with renal medullary carcinoma’, Clinical Genitourinary Cancer, 17(1), pp. 1-6.
- Msaouel, P. et al. (2020) ‘Comprehensive molecular characterization identifies distinct genomic and immune hallmarks of renal medullary carcinoma’, Cancer Cell, 37(5), pp. 720-734.
- Shah, A.Y. et al. (2017) ‘Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study’, BJU International, 120(6), pp. 782-792.
- Soeung, M. et al. (2025) ‘Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence’, Nature Communications, 16(1), 10474.
- National Cancer Institute (2026) Renal Cell Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/kidney/hp/kidney-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.